Cutaneous T-Cell Lymphoma after Dupilumab Use: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System.

HOME
>
論文・技術情報
>
Cutaneous T-Cell Lymphoma after Dupilumab Use: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System.

アブストラクト
ジャーナル名	The Journal of investigative dermatology
投稿日	2024/7/1
投稿者	Lavin, Leore; Dusza, Stephen; Geller, Shamir
組織名	Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer;Center, New York, New York, USA.;Center, New York, New York, USA. Electronic address: gellers@mskcc.org.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/38945437/

タグ:

お問合わせ

キーワード